SFE Investment Counsel’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

SFE Investment Counsel’s Portfolio SBIO Stock Details SBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10,055	Closed	-$425K	–	125
2021 Q4	$425K	Buy	10,055 +627	+7%	+$27.9K	0.11%	99
2021 Q3	$429K	Buy	9,428 +63	+0.7%	+$2.89K	0.12%	98
2021 Q2	$458K	Buy	9,365 +399	+4%	+$19.1K	0.13%	95
2021 Q1	$451K	Sell	8,966 -1,869	-17%	-$103K	0.13%	92
2020 Q4	$555K	Buy	10,835 +2,044	+23%	+$97.3K	0.18%	90
2020 Q3	$362K	Buy	8,791 +66	+0.8%	+$2.72K	0.14%	92
2020 Q2	$365K	Sell	8,725 -829	-9%	-$32.7K	0.16%	85
2020 Q1	$303K	Sell	9,554 -296	-3%	-$11.3K	0.17%	92
2019 Q4	$416K	Sell	9,850 -280	-3%	-$10.4K	0.17%	89
2019 Q3	$320K	Buy	10,130 +520	+5%	+$18.3K	0.14%	99
2019 Q2	$347K	Buy	9,610 +1,826	+23%	+$63K	0.15%	97
2019 Q1	$282K	Buy	+7,784	New	+$260K	0.13%	99

Other funds holding SBIO

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Matisse Capital Portland, Oregon $234M AUM 19.72% 1-Year Est. Return

NAM

NTV Asset Management Charleston, West Virginia $910M AUM 27.02% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

SFS

Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return

BPA

Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SFE Investment Counsel's SBIO Position: Q1 2022 in Review

SFE Investment Counsel sold out of ALPS Medical Breakthroughs ETF (SBIO) in Q1 2022, closing a stake of 10,055 shares — an estimated $425K sold.

SFE Investment Counsel first reported a position in SBIO in Q1 2019 and held it in 12 quarters. The position peaked at $555K in Q4 2020. 56 funds tracked by Wall St. Rank hold SBIO as of Q1 2022.

SFE Investment Counsel reported no remaining ALPS Medical Breakthroughs ETF position as of Q1 2022 after selling out during the quarter.
SFE Investment Counsel sold 10,055 ALPS Medical Breakthroughs ETF shares in Q1 2022, an estimated $425K.
SFE Investment Counsel first reported a position in ALPS Medical Breakthroughs ETF in Q1 2019 and held it in 12 quarters.
SFE Investment Counsel's ALPS Medical Breakthroughs ETF position peaked at $555K in Q4 2020.
56 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q1 2022.

Based on SFE Investment Counsel's 13F filing for Q1 2022, filed 6 May 2022.